Compounds that fight antibiotic resistance in harmful bacteria
GmPcides: Componds that disarm antibiotic resistance in multiple gram-positive pathogens
['FUNDING_OTHER'] · WASHINGTON UNIVERSITY · NIH-11042762
This study is testing new compounds called GmPcides that aim to fight tough bacteria, like MRSA and VRE, which can cause serious infections in hospitals, and if they work, they could help create better treatments for patients dealing with these infections.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (SAINT LOUIS, UNITED STATES) |
| Trial ID | NIH-11042762 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a new class of compounds called GmPcides that target and combat antibiotic-resistant bacteria, particularly those causing hospital-acquired infections. The approach involves using these compounds to not only kill bacteria but also to disarm their resistance mechanisms, making them more susceptible to existing antibiotics. The research includes laboratory tests and animal models to evaluate the effectiveness of GmPcides against various dangerous Gram-positive bacteria, including MRSA and VRE. If successful, this could lead to new treatment options for patients suffering from severe infections.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients suffering from hospital-acquired infections caused by antibiotic-resistant Gram-positive bacteria.
Not a fit: Patients with infections caused by Gram-negative bacteria may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide new treatment options for patients with infections caused by antibiotic-resistant bacteria.
How similar studies have performed: Other research has shown promise in developing compounds that target antibiotic resistance, but the specific approach of GmPcides is novel.
Where this research is happening
SAINT LOUIS, UNITED STATES
- WASHINGTON UNIVERSITY — SAINT LOUIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CAPARON, MICHAEL G. — WASHINGTON UNIVERSITY
- Study coordinator: CAPARON, MICHAEL G.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Airway infections, antibiotic resistant infections